Feb 13, 2019
The hallucinogenic party drug, ketamine has passed the final problem for going into the clinical stage as an antidepressant. The US Food and Drug Administration (FDA), an independent advisory committee, supported in favour of commending a compound known as esketamine, used for treating depression. If the FDA giv...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper